Seres Therapeutics Publishes VOWST Mechanism Research Findings
Seres Therapeutics announced the publication of two manuscripts in Nature Medicine and the Journal of Infectious Diseases highlighting new insights into the functional mechanism and clinical impact of VOWST. Together, these publications provide further validation of the Company's Live Biotherapeutics Products, LBPs, approach and inform the continued development of Seres' pipeline of next-generation LBPs, including its lead investigational candidate, SER-155. The Nature Medicine article, titled "The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome", confirmed Seres pharmacological hypotheses from earlier VOWST studies, with higher VOWST dosing associated with enhanced pharmacokinetics, as assessed by faster and more robust therapeutic species engraftment in the gut. A publication in the Journal of Infectious Diseases, titled "Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection", reported a post hoc analysis of the ECOSPOR IV Phase 3 trial, with data demonstrating that the underlying functional disease etiology is consistent in both first and multiply recurrent CDI patient populations, with VOWST demonstrating similar efficacy and drug pharmacology across the broad patient population.
Trade with 70% Backtested Accuracy
Analyst Views on MCRB
About MCRB
About the author
Seres (MCRB) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Seres Receives Positive Input from FDA on Phase 2 Study Protocol for SER-155; Plans Workforce Reduction
FDA Feedback on SER-155: Seres Therapeutics received constructive feedback from the FDA regarding the Phase 2 study protocol for SER-155, aimed at preventing bloodstream infections in adults undergoing stem cell transplants, which will aid in finalizing the protocol.
Workforce Reduction and Financial Outlook: The company is reducing its workforce by approximately 25%, which is expected to incur cash payments of $1.0 - $1.4 million in Q4 2025, while extending its cash runway into the second quarter of 2026.
Seres Therapeutics reduces workforce by 25% to prolong cash reserves until Q2 2026.
Cost-Cutting Measures: Seres Therapeutics plans to reduce its workforce by about 25% to trim operating costs, which is expected to extend its cash runway into the second quarter of 2026.
SER-155 Study Development: Following positive FDA feedback, the company aims to finalize the Phase 2 study protocol for SER-155, targeting bloodstream infections in adults undergoing stem cell transplants, while seeking capital to support this and other biotherapeutic developments.
Everything You Should Know About Seres Therapeutics (MCRB) Upgrade to Buy Rating
Zacks Rank Upgrade: Seres Therapeutics (MCRB) has been upgraded to a Zacks Rank #2 (Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that Seres Therapeutics is positioned for potential near-term gains, as it falls within the top 20% of Zacks-covered stocks based on these revisions.
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost
Biotech Stocks Surge: Several biotech and medical technology stocks experienced significant gains in after-hours trading, driven by earnings optimism, clinical trial progress, and speculative positioning, with notable movers including Seres Therapeutics and TransMedics.
Key Developments: TransMedics received FDA approval for its heart trial, while Capricor announced a milestone in its vaccine trial. Other companies like Karyopharm and Coya Therapeutics saw stock rebounds despite lacking specific news catalysts, indicating investor anticipation for future developments.
Market Volatility: Stocks such as Meihua International and Jin Medical showed notable price movements without specific news, reflecting technical rebounds and investor positioning in a volatile market environment.
Earnings Reports and Guidance: TransMedics raised its revenue guidance for 2025, projecting significant growth, while other companies are preparing for upcoming earnings reports and trial milestones, contributing to the overall market momentum in the biotech sector.
Robinhood Shares Surge Over 7%; Check Out 20 Stocks Making Moves in Premarket Trading
Robinhood's Market Movement: Robinhood Markets, Inc. shares surged 7.4% in pre-market trading after being announced as a replacement for Caesars Entertainment in the S&P 500, effective September 22.
Other Notable Gainers: Several stocks saw significant pre-market gains, including Eightco Holdings (up 142.1%), Gyrodyne (up 82.1%), and Forward Industries (up 78.8%).
Pre-Market Losers: Citius Oncology experienced a 25% drop, while MEI Pharma and CNFinance also saw declines of 19.3% and 18.8%, respectively, in pre-market trading.
Market Overview: The article provides a snapshot of various stocks' performances, highlighting both significant gainers and losers in the pre-market trading session.
Seres (MCRB) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Seres Receives Positive Input from FDA on Phase 2 Study Protocol for SER-155; Plans Workforce Reduction
FDA Feedback on SER-155: Seres Therapeutics received constructive feedback from the FDA regarding the Phase 2 study protocol for SER-155, aimed at preventing bloodstream infections in adults undergoing stem cell transplants, which will aid in finalizing the protocol.
Workforce Reduction and Financial Outlook: The company is reducing its workforce by approximately 25%, which is expected to incur cash payments of $1.0 - $1.4 million in Q4 2025, while extending its cash runway into the second quarter of 2026.
Seres Therapeutics reduces workforce by 25% to prolong cash reserves until Q2 2026.
Cost-Cutting Measures: Seres Therapeutics plans to reduce its workforce by about 25% to trim operating costs, which is expected to extend its cash runway into the second quarter of 2026.
SER-155 Study Development: Following positive FDA feedback, the company aims to finalize the Phase 2 study protocol for SER-155, targeting bloodstream infections in adults undergoing stem cell transplants, while seeking capital to support this and other biotherapeutic developments.
Everything You Should Know About Seres Therapeutics (MCRB) Upgrade to Buy Rating
Zacks Rank Upgrade: Seres Therapeutics (MCRB) has been upgraded to a Zacks Rank #2 (Buy) due to a significant increase in earnings estimates, indicating a positive outlook for the company's stock price.
Earnings Estimate Revisions: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that Seres Therapeutics is positioned for potential near-term gains, as it falls within the top 20% of Zacks-covered stocks based on these revisions.
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost
Biotech Stocks Surge: Several biotech and medical technology stocks experienced significant gains in after-hours trading, driven by earnings optimism, clinical trial progress, and speculative positioning, with notable movers including Seres Therapeutics and TransMedics.
Key Developments: TransMedics received FDA approval for its heart trial, while Capricor announced a milestone in its vaccine trial. Other companies like Karyopharm and Coya Therapeutics saw stock rebounds despite lacking specific news catalysts, indicating investor anticipation for future developments.
Market Volatility: Stocks such as Meihua International and Jin Medical showed notable price movements without specific news, reflecting technical rebounds and investor positioning in a volatile market environment.
Earnings Reports and Guidance: TransMedics raised its revenue guidance for 2025, projecting significant growth, while other companies are preparing for upcoming earnings reports and trial milestones, contributing to the overall market momentum in the biotech sector.
Robinhood Shares Surge Over 7%; Check Out 20 Stocks Making Moves in Premarket Trading
Robinhood's Market Movement: Robinhood Markets, Inc. shares surged 7.4% in pre-market trading after being announced as a replacement for Caesars Entertainment in the S&P 500, effective September 22.
Other Notable Gainers: Several stocks saw significant pre-market gains, including Eightco Holdings (up 142.1%), Gyrodyne (up 82.1%), and Forward Industries (up 78.8%).
Pre-Market Losers: Citius Oncology experienced a 25% drop, while MEI Pharma and CNFinance also saw declines of 19.3% and 18.8%, respectively, in pre-market trading.
Market Overview: The article provides a snapshot of various stocks' performances, highlighting both significant gainers and losers in the pre-market trading session.
